Trial Profile
A Phase II Study of 506U78 [nelarabine] in Patients With Refractory or Relapsed T-Lineage Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphomas (LBL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Nelarabine (Primary)
- Indications Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 04 Jun 2007 Status changed from 'in progress' to 'completed'
- 11 Oct 2005 New trial record.